HCC - HEPATOCELLULAR CARCINOMA
Clinical trials for HCC - HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HCC - HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for HCC - HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Liver cancer breakthrough: surgery or maintenance after successful conversion therapy?
Disease control Not yet recruitingThis study looks at 100 adults with liver cancer that was initially too advanced for surgery but improved after conversion therapy. Researchers want to see if having surgery or continuing maintenance therapy is better at preventing the cancer from coming back. The goal is to help…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: West China Hospital • Aim: Disease control
Last updated May 17, 2026 07:08 UTC
-
New drug cocktail aims to stop liver cancer return in High-Risk patients
Disease control Not yet recruitingThis study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer that can be removed will be randomly assigned to receive the …
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE3 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 07:07 UTC
-
New drug combo aims to stop liver cancer recurrence before surgery
Disease control Not yet recruitingThis study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in people with early-stage disease at high risk of recurrence. About 30 adults aged 18-75 with resectable stage IB o…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 07:07 UTC
-
New triple therapy aims to control advanced liver cancer without surgery
Disease control Not yet recruitingThis study tests a combination of three treatments—donafenib (a targeted drug), hepatic artery infusion chemotherapy (chemotherapy delivered directly to the liver), and sintilimab (an immunotherapy)—as the first treatment for people with unresectable hepatocellular carcinoma (liv…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 07:04 UTC
-
New drug combo before surgery may slash liver cancer recurrence risk
Disease control Not yet recruitingThis study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can reduce the risk of liver cancer returning in people with early-stage disease. About 60 adults with a single liver tumor (2-5 cm) and a narrow surgical margin will be randomly assigned to re…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 06:49 UTC
-
New study aims to perfect radiation dose for liver cancer
Disease control Not yet recruitingThis study is for adults with liver cancer that cannot be removed by surgery or standard treatments. It tests different doses of radiation delivered directly to the liver to find the amount that completely destroys the tumor. The goal is to improve treatment and understand how li…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Gut bacteria may boost liver cancer treatment before surgery
Disease control Not yet recruitingThis study looks at whether taking a probiotic (Lactobacillus reuteri) before liver cancer surgery, along with standard immunotherapy, helps patients recover better and live longer. About 40 adults with resectable liver cancer will be randomly assigned to receive the probiotic pl…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New quadruple therapy aims to control liver cancer in diabetic patients
Disease control Not yet recruitingThis study tests a combination of four drugs (epalrestat, HAIC chemotherapy, donafenib, and tislelizumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery and who also have diabetes. The goal is to see if this approach can keep the canc…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Haibo Shao • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Could amino acids boost immunotherapy for liver cancer?
Disease control Not yet recruitingThis study tests whether adding branched-chain amino acids (BCAAs) to a standard immunotherapy combination (lenvatinib plus pembrolizumab) helps adults with advanced liver cancer that cannot be removed by surgery. About 234 participants will be randomly assigned to receive the st…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New combo attack on tough liver cancer shows promise in early trial
Disease control Not yet recruitingThis study tests a three-part treatment for people with liver cancer that has spread into a major liver blood vessel. Participants will receive radiation therapy plus two drugs (tislelizumab and anlotinib) to shrink tumors and control the disease. The goal is to see how many pati…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New combo therapy aims to slow liver cancer progression in tough cases
Disease control Not yet recruitingThis study tests whether adding a procedure called endovascular denervation (EDN) to standard treatments (TACE/HAIC plus immune-targeted therapy) can help people with advanced liver cancer that has spread to the portal vein and has not responded to initial therapy. About 62 adult…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Zhongda Hospital • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for tough liver cancers: triple therapy targets gene mutation
Disease control Not yet recruitingThis study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in 25 adults with advanced liver cancer that has a TP53 gene mutation and has not responded to previous immunotherapy. The goal is to see if the combination can shrink tumors and control the d…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
AI tool could spare half of liver cancer patients from needless treatment
Knowledge-focused Not yet recruitingThis study looks back at data from 400 liver cancer patients to build an AI system that predicts how well they will respond to a standard treatment (atezolizumab plus bevacizumab). The goal is to identify which patients are likely to benefit before starting therapy, avoiding unne…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC